|Slideshows|November 14, 2018

Dermatoses of Childhood: 7 Photoclinic Cases

Can you diagnose these 7 cases of dermatoses? Scroll through our Photoclinic to find out.

These seven Photoclinic cases offer a good look at and a brief overview of common dermatologic conditions of childhood. (This presentation updates the original, posted in 2016.)

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Dermatoses of Childhood: 7 Photoclinic Cases

Related Content

Zasocitinib Tops Deucravacitinib for Skin Clearance in Phase 3 Psoriasis Trial

Tirzepatide Plus Ixekizumab Improves Outcomes in Psoriatic Arthritis With Obesity: AAD 2026

Lebrikizumab Maintains Efficacy Through 4 Years in Moderate-to-Severe Atopic Dermatitis: AAD 2026

Icotrokinra for Moderate-to-Severe Plaque Psoriasis: A Dermatologist's Guide for Primary Care

FDA Approves Icotrokinra (Icotyde): First Oral IL-23 Receptor Antagonist for Moderate-to-Severe Plaque Psoriasis

Latest CME

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Wisconsin Association of Hematology and Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Rhode Island Oncology Society

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

South Carolina Oncology Society

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

20th Annual New York Lung Cancers Symposium®

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

ISGIO 2025: Esophageal and Gastric Cancer

ISGIO 2025: Hepatobiliary Cancers

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Optimizing Multidisciplinary Care in TGCT

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Empowering HIV Management: Evidence-Based Prevention and Treatment Strategies

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

North Carolina Oncology Association

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Community Practice Connections™: 18th Annual New York GU Cancer Congress™

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)